Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 227.71 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; hydrochloric acid; sodium hydroxide; mannitol - gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcitabine drla in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcitabine drla in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 1138.52 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium acetate trihydrate; mannitol - gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcitabine drla is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcitabine drla in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcitabine drla in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 2.28 g (equivalent: gemcitabine, qty 2 g) - injection, powder for - excipient ingredients: sodium hydroxide; sodium acetate; hydrochloric acid; mannitol - gemcitabine injection is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,gemcitabine injection is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine an for injection is also indicated for patients with 5-fu refractory pancreatic cancer.,gemcitabine injection, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,gemcitabine injection, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.,gemcitabine injection, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 1138.526 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sodium acetate; hydrochloric acid - gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine an for injection is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine an for injection, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine an for injection, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine an for injection, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed >6 months following platinum-based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 227.705 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium acetate; mannitol - gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. gemcitabine an for injection is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine an for injection is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine an for injection, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine an for injection, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine an for injection, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed >6 months following platinum-based therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - gemcitabine hydrochloride 1138.53mg equivalent to 1000 mg gemcitabine;   - powder for injection - 1 g - active: gemcitabine hydrochloride 1138.53mg equivalent to 1000 mg gemcitabine   excipient: hydrochloric acid mannitol sodium acetate sodium hydroxide - gemcitabine, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - gemcitabine hydrochloride 227.705mg equivalent to 200 mg gemcitabine;   - powder for injection - 200 mg - active: gemcitabine hydrochloride 227.705mg equivalent to 200 mg gemcitabine   excipient: hydrochloric acid mannitol sodium acetate sodium hydroxide - gemcitabine, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - gemcitabine hydrochloride 2227.05mg equivalent to 2000 mg gemcitabine;   - powder for injection - 2 g - active: gemcitabine hydrochloride 2227.05mg equivalent to 2000 mg gemcitabine   excipient: hydrochloric acid mannitol sodium acetate sodium hydroxide - gemcitabine, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - gemcitabine hydrochloride 1138mg equivalent to gemcitabine 1 g - powder for infusion - 1000 mg - active: gemcitabine hydrochloride 1138mg equivalent to gemcitabine 1 g excipient: hydrochloric acid mannitol sodium acetate trihydrate sodium hydroxide - gemcitabine, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - gemcitabine hydrochloride 1138.53mg equivalent to 1000 mg gemcitabine;   - powder for injection - 1 g - active: gemcitabine hydrochloride 1138.53mg equivalent to 1000 mg gemcitabine   excipient: hydrochloric acid mannitol sodium acetate sodium hydroxide - gemcitabine, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.